SCHEMBL196536

SCHEMBL196536

Clc1ccc(Cl)c2ncccc12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.70
HSP90AA1 P07900 5/20 0.70
MAPT P10636 4/20 0.70
LMNA P02545 3/20 0.70
METAP2 P50579 2/20 0.70
METAP1 P53582 2/20 0.70
BRD4 O60885 1/20 0.70
ALDH1A1 P00352 5/20 0.59
L3MBTL1 Q9Y468 3/20 0.59
CCR1 P32246 1/20 0.59
CCR8 P51685 1/20 0.59
CYP3A4 P08684 3/20 0.57
ALOX12 P18054 3/20 0.57
TDP1 Q9NUW8 3/20 0.57
MMP14 P50281 3/20 0.57
HTT P42858 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
MEN1 O00255 2/20 0.57
TP53 P04637 2/20 0.57
ALOX15 P16050 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21081235 0.86 KDM4E (0.66) KDM4EHSP90AA1MAPTLMNAMETAP2
SCHEMBL318769 0.84 NR4A2 (0.68) KDM4EHSP90AA1MAPTLMNAMETAP2
SCHEMBL29410781 0.84 NR4A2 (0.68) KDM4EHSP90AA1MAPTLMNAMETAP2
SCHEMBL2095713 0.83 KDM4E (0.61) KDM4EHSP90AA1MAPTLMNAMETAP2
SCHEMBL3559305 0.83 KDM4E (0.61) KDM4EHSP90AA1MAPTLMNAMETAP2
Cloxyquin SCHEMBL1714836 0.83 KDM4E (0.61) KDM4EHSP90AA1MAPTLMNAMETAP2
SCHEMBL10159159 0.83 KDM4E (0.61) KDM4EHSP90AA1MAPTLMNAMETAP2
SCHEMBL2056205 0.83 KDM4E (0.61) KDM4EHSP90AA1MAPTLMNAMETAP2
SCHEMBL18980424 0.83 KMT2A (0.59) KDM4EHSP90AA1MAPTLMNAMETAP2
Cloxyquin SCHEMBL115838 0.83 KDM4E (1.00) KDM4EHSP90AA1MAPTLMNAMETAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023124205-A1 ORGANIC COMPOUNDS, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS 陕西莱特光电材料股份有限公司 2023-07-06 WO disclosed
US-8293905-B2 Bipyridine compound, transition metal complex, and method for production of conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-10-23 US disclosed
US-8088883-B2 Transition metal complex and process for producing conjugated aromatic compound using the transition metal complex SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-03 US disclosed
US-20110046336-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED 2011-02-24 US disclosed
US-20100292481-A1 METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED 2010-11-18 US disclosed
EP-2233459-A1 METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND Sumitomo Chemical Company, Limited (JP) 2010-09-29 EP disclosed
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-07-22 US disclosed
EP-2192124-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND WITH THE TRANSITION METAL COMPLEX Sumitomo Chemical Company, Limited (JP) 2010-06-02 EP disclosed
EP-2172470-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX Sumitomo Chemical Company, Limited (JP) 2010-04-07 EP disclosed
US-20090326188-A1 Method for producing polyarylene SUMITOMO CHEMICAL COMPANY, LIMITED 2009-12-31 US disclosed
US-5886130-A THE CO-POLYMERS ARE USEFUL AS MOLDING RESINS, AND COMPOSITE MATRIX RESINS, AND WHERE AR IS HETEROARYLENE AS ION EXCHANGE RESINS. MAXDEM INCORPORATED (US) 1999-03-23 US disclosed
US-5827927-A Macromonomers having reactive end groups MAXDEM INCORPORATED (US) 1998-10-27 US disclosed
US-5824744-A RIGID POLYMER RODS AND MACROMONOMERS WITH REACTIVE END GROUPS FOR REINFORCEMENT MAXDEM INCORPORATED (US) 1998-10-20 US disclosed
US-5736274-A ANODE ACTIVE MATERIAL AND SOLID ELECTROLYTE FOR BATTERIES; HIGH ELECTROMOTIVE FORCE; HIGH ENERGY DENSITY; POLLUTION CONTROL; FLUORINATING AGENTS; LOW INTERNAL RESISTANCE IN CHARGING AND DISCHARGING DAIKIN INDUSTRIES, LTD. (JP) 1998-04-07 US disclosed
US-5670564-A Macromonomers having reactive end groups MAXDEM INCORPORATED (US) 1997-09-23 US disclosed
EP-0787719-A1 CONJUGATED N-FLUOROPYRIDINIUM SALT POLYMER AND USE THEREOF DAIKIN INDUSTRIES, LTD. (JP) 1997-08-06 EP disclosed
EP-0773249-A1 Polyphenylene co-polymers MAXDEM INCORPORATED (US) 1997-05-14 EP disclosed
EP-0599886-A4 MACROMONOMERS HAVING REACTIVE END GROUPS. MAXDEM INC (US) 1996-07-24 EP disclosed
EP-0599886-A1 MACROMONOMERS HAVING REACTIVE END GROUPS MAXDEM INCORPORATED (US) 1994-06-08 EP disclosed
WO-1993004099-A1 MACROMONOMERS HAVING REACTIVE END GROUPS MAXDEM INCORPORATED (US) 1993-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046336-A1 TRANSITION METAL COMPLEX AND PROCESS FOR PRODUCING CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX C9, C5, AP1M1 KDM4E 1741/4885HSP90AA1 3522/4885MAPT 783/4885
US-20100184978-A1 BIPYRIDINE COMPOUND, TRANSITION METAL COMPLEX, AND METHOD FOR PRODUCTION OF CONJUGATED AROMATIC COMPOUND USING THE TRANSITION METAL COMPLEX C9, C5, AP2M1 KDM4E 2705/4885HSP90AA1 3425/4885MAPT 1124/4885
US-20100292481-A1 METHOD FOR PRODUCING CONJUGATED AROMATIC COMPOUND TYR, PAH, AHR KDM4E 524/4885HSP90AA1 2867/4885MAPT 491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.